Treatments for moderate-to-severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study compares the effectiveness of a pill (upadacitinib) with several biologic injections (biologics are medicines that target specific parts of the immune system) in controlling moderate-to-severe atopic dermatitis (eczema). The goal is to see which treatment helps people achieve minimal disease activity, meaning their eczema is under good control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a doctor's diagnosis of moderate-to-severe atopic dermatitis (eczema).
- Your eczema symptoms began at least 1 year ago.
- You are about to start treatment with upadacitinib or an approved biologic for eczema, as prescribed by your doctor.
- You are willing to fill out questionnaires about your eczema and quality of life.
- You have not used the specific treatment you are starting before.
- You are not currently participating in another interventional study (but being in a registry is okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
This study looks at how well abrocitinib (a daily pill) works for people with moderate to severe eczema who have already tried biologic medicines and didn't get enough relief. It aims to see if this treatment can help you better manage your eczema.
This study tests a new medication called IBI356 for people with moderate to severe eczema that hasn't improved with standard creams. The goal is to see if this medicine can safely reduce the redness, itching, and rash.
This study tests a daily pill, abrocitinib, to see if it safely reduces severe eczema (atopic dermatitis) in children aged 2 to under 6 years. It may help when creams or other treatments haven't worked well enough.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.